Investor Relations

    LivaNova is committed to enhancing shareholder value driven by our Vision and Mission. We are a market-leading medical technology company creating ingenious medical solutions that ignite patient turnarounds for people around the world.

    Explore Our Investor Kit
    NASDAQ GS: LIVN
    Day High
    Day Low
    Volume

    Data Provided by Refinitiv. Minimum 15 minutes delayed.

    Show all
    April 29, 2026
    2025 US Annual Report
    April 29, 2026
    2025 UK Annual Report
    April 29, 2026
    2026 Proxy Statement

    Pro forma revenues by geography 1

    • Europe
    • United States
    • Rest of World

    1) Rounded numbers based on full-year 2025 revenue.

    Pro forma revenues by business 1

    • Cardiopulmonary
    • Neuromodulation

    1) Rounded numbers based on full-year 2025 revenue.

    News Listing Image

    Recent Press Releases

    April 20, 2026
    Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
    March 25, 2026
    LivaNova to Announce First-Quarter 2026 Results
    March 19, 2026
    LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
    February 25, 2026
    LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
    Top